DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and
pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be
enrolled into this study.